September 16, 2022 | BOTOX® Cosmetic, Daxxify neurotoxin
1 minute read
Biotechnology company Revance issued a press release this month announcing the FDA approval of Daxxify (DaxibotulinumtoxinA-Ianm) for the treatment of frown lines.
Findings from clinical trials using Daxxify found the average duration of action of the neurotoxin at approximately 6 months, compared to 3~4 months of other neurotoxins, such as Botox and Dysport, while enjoying a similar safety profile.
This is very promising news indeed, if our patients can enjoy year-long results with as few as two treatments per year using Daxxify.
Reserve your spot by phone (713) 526-5665 or email mailbox@todaysface.com if you are interested in trying Daxxify when it becomes commercially available.
